Bristol-Myers Sets $160 Million Tax Reserve for Transfer Pricing

Pharmaceutical giant Bristol-Myers Squibb Co. set aside $160 million in additional tax reserves last quarter related to “transfer pricing matters,” the company reported Thursday.

The company is currently contesting several proposed adjustments from the IRS relating to its transfer pricing and other tax issues for the years 2008 through 2012, it said in the 10-Q statement for the third quarter of 2025 it filed with the US Securities and Exchange Commission. The company appealed these adjustments in 2022.

The filings didn’t specify how much the IRS was seeking in the adjustments, but it did say the company may ...